244 related articles for article (PubMed ID: 9930386)
1. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
Qvigstad G; Arnestad JS; Brenna E; Waldum HL
Scand J Gastroenterol; 1998 Dec; 33(12):1244-8. PubMed ID: 9930386
[TBL] [Abstract][Full Text] [Related]
2. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
[TBL] [Abstract][Full Text] [Related]
3. Drugs, bugs, and esophageal pH profiles.
Robinson M
Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Abdul-Hussein M; Freeman J; Castell D
Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
6. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
7. Drug therapy of peptic ulcer disease.
Ching CK; Lam SK
Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
[TBL] [Abstract][Full Text] [Related]
8. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
[TBL] [Abstract][Full Text] [Related]
9. Nocturnal acid breakthrough: pH, drugs and bugs.
Tutuian R; Katz PO; Castell DO
Eur J Gastroenterol Hepatol; 2004 May; 16(5):441-3. PubMed ID: 15097034
[TBL] [Abstract][Full Text] [Related]
10. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
Holtmann G; Layer P; Goebell H
Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357
[TBL] [Abstract][Full Text] [Related]
11. Combination drug therapy for gastroesophageal reflux disease.
Cross LB; Justice LN
Ann Pharmacother; 2002 May; 36(5):912-6. PubMed ID: 11978171
[TBL] [Abstract][Full Text] [Related]
12. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Bardou M
Rev Prat; 2001 Apr; 51(7):789-95. PubMed ID: 11387678
[No Abstract] [Full Text] [Related]
13. Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole.
Savarino V; Bisso G; Pivari M; Zentilin P; Bilardi C; Dulbecco P; Mele MR; Tracci D; Vigneri S
Aliment Pharmacol Ther; 2000 Mar; 14(3):291-7. PubMed ID: 10735921
[TBL] [Abstract][Full Text] [Related]
14. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Langtry HD; Wilde MI
Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
[TBL] [Abstract][Full Text] [Related]
16. [Cause and prevention of nocturnal gastric acid breakthrough].
Adachi K; Kinoshita Y
Nihon Rinsho; 2002 Feb; 60 Suppl 2():779-83. PubMed ID: 11979888
[No Abstract] [Full Text] [Related]
17. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.
Fackler WK; Ours TM; Vaezi MF; Richter JE
Gastroenterology; 2002 Mar; 122(3):625-32. PubMed ID: 11874994
[TBL] [Abstract][Full Text] [Related]
18. Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent?
Smout AJ
Scand J Gastroenterol Suppl; 1998; 225():32-5. PubMed ID: 9515750
[TBL] [Abstract][Full Text] [Related]
19. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
[TBL] [Abstract][Full Text] [Related]
20. Acid pump blockers: what are their current therapeutic roles?
Arens MJ; Dent J
Baillieres Clin Gastroenterol; 1993 Mar; 7(1):95-128. PubMed ID: 8097414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
